The Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions


  • Roberto Ravasio HEOR & RWE Lead, Market Access Provider, Milano (MI) - Italy
  • Paola Raimondo MAA, Market Access Provider, Milano (MI) - Italy



Cost minimization, Diarrhoea, Enterosgel®, Hospital bed, Hospital stay


Background: Enterosorbents are orally administered materials which pass through the gut where they bind various substances. In a randomized clinical trial, the efficacy and safety of enterosorbent Enterosgel® in the treatment of non-infectious diseases with diarrhoea have been proved.

Objective: To assess the cost impact of Enterosgel® in the treatment of hospitalized patients with non-infectious diseases with diarrhoea adopting a cost/minimization approach.

Methods: A cost analysis was conducted considering the hospital’s perspective. The analysis compared the treatment costs (drugs and hospital stays) of Enterosgel® in addition to the standard of care (SoC) to SoC alone. The main analysis focused on the comparison between the two therapeutic strategies regarding the economic valorization of hospital stays, while the secondary analysis estimated the hospital organizational efficiency with regard to the annual bed turnover.

Results: Reducing the duration of inpatient admission, compared to SoC alone, Enterosgel® in addition to SoC let the hospital obtain a greater valorization of the hospital stays (range: € 68.54-€ 558.60). The shorter duration of inpatient admission results in an increased number of hospital admissions per year. For example, assuming a 10-bed ward, the total hospital annual gain would be € 82,616.

Conclusions: Enterosgel® in addition to SoC is cost saving, allowing the hospital to achieve greater efficiency in managing patients with non-infectious diseases with diarrhoea.


Gnerre P., Attardo T.M. a nome del Gruppo FADOI Giovani. Management del paziente con diarrea, nausea e vomito, malnutrizione e malattia celiaca: lo stato dell’arte. Italian Journal of Medicine 2016;4(3): 1-96. (accessed September 2021) DOI:

ISSalute. Istituto Superiore di Sanità. Diarrea. 2018. (accessed September 2021) Rete Pediatrica di Epidemiologia e Ricerca. La diarrea. (accessed September 2021)

Pavlov A.I., Fadina Z.V. Tactics of management of diarrhea of noninfectious genesis in a hospital. Voenno-medicinskij žurnal. 2018;339(6):49-54. (accessed September 2021)

Paliy IG, Reznichenko IG. A modern view on the issue of enterosorption: Choosing the optimal drug. Liky Ukrainy. 2008;6(122):43-46. Medications of Ukraine. Online (accessed September 2021)

Gastroenterology. Detoxifing agent Enterosgel®. New Approaches. Collection of Research Papers. 2014 Bioline Products s.r.o. Online (accessed September 2021)

Sheyman BS, Bagdasarova IV, Osadchaya OI, et al. The selective detoxifying properties of the enterosorbent Enterosgel® and optimization of the therapeutic indications. Sovremennye problemy toksikologii. 2004; 3:79–83 (in Ukrainian). Online (accessed September 2021)

Nagornaya N. V., Dubovaya A. V. The Detoxifying Potential and Clinical Effectiveness of the Enterosorbent Enterosgel® in the Combination Therapy of Various Diseases in Children and Adults. Zdorove rebenka [Child health]. 2010; 3:65–70 (in Russian). Online (accessed September 2021)

Howell CA, Mikhalovsky SV, Markaryan EN, Khovanov AV. Investigation of the adsorption capacity of the enterosorbent Enterosgel for a range of bacterial toxins, bile acids and pharmaceutical drugs. Sci Rep. 2019 Apr 4;9(1):5629. . PMID: 30948767 DOI:

Kemppinen A, Howell C, Allgar V, et al. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Trials. 2020;21(1):122. PMID:32000822 DOI:

Tariffe delle Prestazioni di Assistenza Ospedaliera per acuti, per tipo di ricovero (euro). Supplemento ordinario n. 8 alla Gazzetta Ufficiale Serie Generale - n. 23, 28-1-2013. Online (accessed September 2021)

Fattore, G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia.Pharmacoeconomics-Ital-Res-Articles 11, 83–93 (2009). DOI:

Enterosgel® research. List of clinical studies with Enterosgel®. 2015 (accessed September 2021)

Howell CA, Markaryan E, Allgar V, et al. Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial. BMJ Open Gastroenterol. 2019;6(1):e000287. PMID:31139427 DOI:

Maev IV, Vyuchnova ES, Lebedeva EG, Petukhov AB, Andreev NG. Clinical and therapeutic prophylactic uses of Enterosgel® in patients with gastrointestinal disorders. In: Maev IV, Shevchenko YuN, Petukhov AB, ed. Clinical application of Enterosgel® in patients with gastrointestinal disturbances: novel approaches to treatment. Guidelines for physicians. M.: 2000:15-21

Chernobrovyy VN, Paliy IG. Use of the enterosorbent Enterosgel® in therapy of intestinal dysbiosis. Mystectvo likuvannja. 2003; 5:74 (in Russian).

Petukhov AB, Lysikov YuA, Shakhovskaya AK, et al. Outcomes of Enterosgel® therapy in the treatment of gastrointestinal diseases associated with digestion and absorption abnormalities. In: Maev IV, ShevchenkoYuN, PetukhovAB, Clinical application of Enterosgel in patients with gastrointestinal disturbances: novel approaches to treatment: Guidelines for physicians. 2000:21–27



How to Cite

Ravasio R, Raimondo P. The Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions. abtpn [Internet]. 2021 Dec. 16 [cited 2022 Aug. 11];8(1):99-105. Available from:



Original research article

Most read articles by the same author(s)